In a study designed to evaluate the potential for in vivo manipulation of the circulation and tissue distribution of injected liposomes, mice were passively injected with antidinitrophenyl (anti-DNP) monoclonal antibodies of the IgG2a or IgG2b subclasses or were immunized with the nitrophenyl hapten bound to a protein carrier. They were then injected i.v. with 12'I-and carboxyfluorescein-labeled, DNPbearing liposomes. Circulation time of the DNP-bearing liposomes was markedly reduced in actively and passively immune mice, with increased deposition of liposomes in the liver. The increased clearance of liposomes could be abrogated by injection of a monoclonal antibody directed against the murine IgG Fc receptor (2.4G2). The results suggest that clearance of ligand-bearing reagent in the face of an immune response may be modified by specific immunologic manipulation in vivo.
ABSTRACT
In a study designed to evaluate the potential for in vivo manipulation of the circulation and tissue distribution of injected liposomes, mice were passively injected with antidinitrophenyl (anti-DNP) monoclonal antibodies of the IgG2a or IgG2b subclasses or were immunized with the nitrophenyl hapten bound to a protein carrier. They were then injected i.v. with 12'I-and carboxyfluorescein-labeled, DNPbearing liposomes. Circulation time of the DNP-bearing liposomes was markedly reduced in actively and passively immune mice, with increased deposition of liposomes in the liver. The increased clearance of liposomes could be abrogated by injection of a monoclonal antibody directed against the murine IgG Fc receptor (2.4G2). The results suggest that clearance of ligand-bearing reagent in the face of an immune response may be modified by specific immunologic manipulation in vivo.
The production of monoclonal antibodies (mAbs) of defined specificity has stimulated clinical interest, notably in the identification of normal cellular subsets or tumor cells in vitro, imaging in vivo, and elimination oftumor cells or T cells responsible for graft rejection. For these purposes, mAbs have been used alone (1, 2) or have been linked to radionuclides (3), toxins (4), drugs (5), or particulate carriers such as liposomes (6) (7) (8) . Other similarly coupled ligands, including carbohydrates and hormones, have also been studied for their diagnostic or therapeutic potential (9, 10) .
A major problem associated with these directed reagents in vivo is access to the target cells when they are not in the circulatory system (11) . Important barriers exist even for interaction with those cellular targets that are accessible to the circulation. These barriers include cells of the reticuloendothelial system (RES) (11) . This system is capable of recognizing elements to be cleared by virtue of receptors that, depending on the structure of the complex, are independent of (12) , or dependent on (13) , accessory molecules (opsonins) present in the blood. In addition to natural opsonins, preexisting antibodies may cross-react with the targeting ligand or with the product to be delivered. Moreover, the targeting ligands or substances coupled to them may induce immune responses in the recipient (1, 14) . These induced or preformed antibodies may compete with the cellular target molecules and also augment uptake of the complex by receptors on cells of the RES, such as those for the Fc portion of IgG (15) or of complement (16) , limiting subsequent usefulness of the complex.
Particulate carriers such as liposomes are especially affected by these factors. Depending to some extent on their composition and size, liposomes may be efficiently cleared from the circulation, notably by fixed macrophages of the liver, spleen, and lung (11) . This property has been useful for the delivery of liposome-encapsulated drugs to the RES, as for the treatment offungal (17) or parasitic infections (18) and for augmenting the tumoricidal activity of macrophages (19) , but is an undesirable characteristic when the target cells are not macrophages. Natural antibodies to liposome components exist in some species (20) and liposomes may interact directly, or via C reactive protein, with complement components (21) or with other uncharacterized serum proteins (22) . Finally, liposomes are excellent adjuvants (23) and would be expected to stimulate immune responses directed against them or to ligands coupled to them. All of these circumstances may tend to reduce the capacity of liposomes to deliver molecules elsewhere than to phagocytes. However, the impact of such an immune response remains unknown, since no study has actually determined the effect of an antiligand immune response on the circulation of ligand-bearing liposomes.
Several in vitro studies have demonstrated that, for efficient uptake of liposomes by Fc receptor (FcR)-bearing peritoneal macrophages (24) or macrophage-like tumor cells (25, 26) , it was necessary to opsonize liposomes with passively administered antibodies to liposome-bound ligands. As part of the present experiments, mice either received antidinitrophenyl (anti-DNP) mAbs ofdifferent IgG subclasses passively or were immunized to respond to DNP. We evaluated the influence of passive or elicited anti-DNP antibodies on the circulation and tissue distribution of i.v. injected DNP-bearing liposomes.
Recently, Kurlander et al. (27) showed that the anti-FcR mAb 2.4G2 (28) was able to augment the circulation in mice of preformed complexes of human serum albumin-rabbit anti-human serum albumin, principally by inhibiting the FcR-mediated uptake of injected complexes. This study suggested to us that in vivo manipulation of the FcR may be possible, so we evaluated the ability of the anti-FcR mAb 2.4G2 to influence the distribution of injected liposomes in the presence of accelerated immune elimination. phosphatidylethanolamine (125I-PtdEtn), prepared by the technique of Schroit (29) using dipalmitoyl phosphatidylethanolamine (Sigma) modified by the monoiodo form of the Bolton-Hunter reagent (New England Nuclear), were mixed in benzene/methanol (9:1) and evaporated from organic solvent. Small liposomes, prepared by probe sonication under nitrogen for 30 min at 50TC [as described in detail (25) ], contained 80 mM purified (30) carboxyfluorescein (CFlu) (Kodak) in 100 mM NaHCO3. Liposomes were ultracentrifuged at 100,000 x g for 1 hr and sterilized by filtration (Millipore, 0.45 ,um) before use.
Antibodies. mAbs used are described in Table 1 . Anti-DNP mAbs, resulting from fusion of spleen cells from BALB/c mice immune to DNP-keyhole limpet hemocyanin (KLH) and the NS-1 myeloma, were kindly provided by Z. Eshhar. Cells producing anti-FcR mAb 2.4G2, isolated by J. Unkeless (28) , were a gift from D. Segal. B1.23.2 was from B. Malissen (31) . Isotypes of the anti-DNP mAbs were confirmed by double diffusion in gels using subclass-specific goat antimouse Ig sera (Nordic, Tilburg, The Netherlands). mAbs were ultracentrifuged before use to eliminate aggregates.
Mice. BALB/c (Janvier, France) mice were age-(<16 weeks) and sex-matched in any given experiment. Four or five mice were used for each test point. Values represent mean ± SD for each group, except where the response of individual mice is specified.
Antibody IiNjections. Variable amounts of anti-DNP and control mAbs or 120 jig of anti-FcR were injected i.p. in a total volume of 0.2 ml, 90 min before i.v. injection of liposomes. At this time the level of anti-DNP mAb in the blood was about 30% of the total quantity injected and remained at about this level for several hours (data not shown).
Immunization and Measurement of Antibodies. BALB/c mice were immunized by three i.p. injections of KLH substituted with 40-50 ,umol of trinitrophenyl (TNP) hapten per g of KLH (100 ug per injection in saline at 10-day intervals). Liposome circulation and distribution were assayed 1 week after the third injection. Just prior to this testing, the level of elicited antibodies cross-reactive with DNP was measured by an ELISA technique (32) . The result presented in ,ug of antibodies per ml of serum was based upon a reference curve of known concentrations of the anti-DNP mAb U7.27.
Liposome Circulation. 125I-labeled DNP-liposomes containing CFlu, diluted in Hepes (10 mM)-buffered saline at pH 7.45, were injected i.v. by way ofthe lateral tail vein, in a total volume of 0.2 ml so that each mouse received about 300 nmol of lipid and 30 nmol of CFlu. The analysis of liposome circulation was essentially as described by Kirby et al. (33) . Fifty microliters of blood was collected at intervals from the retroorbital plexus with a microcapillary tube, diluted into 0.5 ml of buffered saline containing 200 international units of heparin per ml, and centrifuged. Supernatant fluids were measured for 125I and CFlu, before and after lysis of liposomes with Triton X-100 detergent. The CFlu quenching ratio was calculated and compared to its value in the original liposome preparation, indicating that <10% of the fluorescence signal was due to free CFlu (34) . The percentage of CFlu or 125I remaining in the circulation is based upon the dilution of liposomes into a blood volume assumed to be 8% of the weight determined for each mouse (33) . The curves of liposome circulation were in total agreement when measured for 125I or for CFlu; thus, both of these levels are indicated on figure ordinates; the SD is based on the CFlu measurements. '25I-Labeled DNP-Liposome Tissue Distribution. Mice were killed by cervical dislocation 90 min after liposome injection.
Tissue radioactivity is expressed as % of the total injected.
125I-Labeled Anti-FcR mAb. To assess its tissue distribution in mice, the anti-FcR mAb was labeled with 1251I using lodo-Gen (35) . The specific activity of the 125I-labeled antiFcR mAb was about 375 mCi (13.8 GBq)/,umol. It was immediately mixed either with the control anti-human mAb (1 mg/ml in saline buffer) or with the nonradiolabeled homologous anti-FcR mAb (1 mg/ml) to a final concentration of 1 ,Ci (37 kBq)/ml and dialyzed against saline buffer. Mice received 0.2 ml of one or the other of these preparations. Ninety minutes later the radioactivity in blood and in different organs was determined.
RESULTS
Effect of Anti-FcR mAb on the Circulation of DNP-Liposomes in Mice Injected with Anti-DNP mAbs of Different IgG Subclasses. Mice were divided into four groups and injected i.p. with an IgG2b anti-DNP or a control anti-HLA mAb. Ninety minutes later DNP-liposomes were injected i.v. and mice were bled at intervals to assess liposome circulation. Results of a representative experiment (Fig. 1) show that the injection of anti-DNP mAb reduced the circulation of DNPliposomes and that the reduction in the circulation of liposomes was proportional to the quantity of anti-DNP antibody injected. Injection of the control mAb had no effect on liposome circulation with respect to uninjected mice (not shown).
Other groups of mice were injected i.p. with the two IgG subclasses. To evaluate the contribution of the FcR in the elimination of DNP-liposomes opsonized with anti-DNP mAb, we also injected mice with the anti-FcR mAb. Fig. 2 shows that liposome clearance curves were altered when mice received anti-FcR mAb together with anti-DNP mAb but not with the control anti-human mAb. In the presence of anti-DNP mAbs, and independent of their subclass, injection of anti-FcR mAb reduced the blood clearance of DNP-liposomes toward the value for mice not receiving anti-DNP mAbs.
To assess the effect of anti-FcR mAb in a more physiological situation, we immunized mice with TNP-KLH, so that mice developed antibodies cross-reactive with DNP ( Table  2 ). Fig. 3 shows that the circulation of DNP-liposomes was reduced in immune mice, essentially in proportion to the magnitude of the immune response (see mice Bi and B2). We evaluated the effect of the anti-FcR mAb on the circulation of DNP-liposomes in DNP-immune mice ofgroup C. Despite the presence of anti-DNP antibodies in these mice (Table 2) , the circulation of DNP-liposomes was nearly normal (Fig. 3) , as observed previously when immunization was mimicked by passive injection of anti-DNP mAbs in the presence of the anti-FcR.
Effect of the Anti-FcR nAb on the Tissue Distribution of DNP-Liposomes in Passively Immune Mice. We determined the tissue distribution of DNP-liposomes in the presence or absence of anti-DNP and anti-FcR mAbs. Fig. 4 shows that, in the presence of IgG2b anti-DNP mAb, 1251 tissue levels were augmented in the liver and intestine. The percentage of l251 in the spleen, kidney, and lung and also (not shown) in the heart and stomach was low, and differences observed in the presence ofthe anti-DNP mAb are probably the consequence of reduced levels of 1251-labeled liposomes in the blood in these organs at the time of sacrifice. In Fig. 4 , the effect of anti-FcR mAb on the distribution of DNP-liposomes is also presented. Infusion of anti-FcR mAb did not modify 1251 distribution in the absence of anti-DNP mAb. By contrast, in the presence of an anti-DNP mAb of the IgG2b subclass, the anti-FcR mAb reduced 125I sequestration in the liver and intestine to levels similar to those of mice not receiving anti-DNP mAb. Essentially the same tissue distribution and effect of the anti-FcR mAb were seen for mice receiving the IgG2a anti-DNP (not shown). We obtained similar results for the distribution of I251-PtdEtn-labeled DNP-liposomes in immunized mice (Fig. 5) . The quantity of 125I sequestered in the liver and intestine correlated with the decrease in the circulation of DNP-liposomes and with the level of anti-DNP antibodies in each mouse.
Tissue Distribution of mI-Labeled Anti-FcR mAb. We compared tissue distribution of i.v. injected 125I-labeled anti-FcR mAb and opsonized '251-labeled DNP-liposomes. The principal target for 125I-labeled anti-FcR mAb was the liver (84.6% of dose recovered 1.5 hr after injection)-not, as in the case of opsonized DNP-liposomes, the intestine (2.4%). Coinjection with a 2500-fold molar excess of nonradiolabeled anti-FcR mAb considerably decreased liver uptake (24.9%) with concomitant increases in blood levels (from 7.4% to 56.0%o of dose recovered), demonstrating that most of the liver uptake of the anti-FcR mAb was specific.
DISCUSSION
Mice passively or actively immune to DNP had markedly accelerated blood clearance kinetics of DNP-bearing small liposomes with respect to nonimmune mice. This clearance was a function of the magnitude of the antibody level and resulted in increased tissue uptake by the liver, which also represents the principal site of deposition of injected liposomes in nonimmune mice (11) . Passive antibodies specific for liposome-bound ligands may augment clearance kinetics of the liposomes, which may be of value in treatment of fungal (17) or parasitic infections (18) or in the activation of tumoricidal macrophages (19) . Liposomes are known to interact with complement in addition to, or as a consequence of, fixation of antibody (21) . Two studies indicate that FcR and complement C3b receptors of murine macrophage-like tumor cells (39) or of peritoneal macrophages (40) are functionally independent with respect to endocytosis in that the internalization of the former did not effect the expression of the latter. However, a recent study showed that the FcR and the C3b receptors of human neutrophils co-capped following binding of ligands specific for one or the other molecule (41) . Whether the FcR and C3b receptors are independent in the in vivo situation studied here or whether the C3b or other receptors are quantitatively unimportant in the absence of effective FcR function remains to be determined. Antiidiotypic responses against injected murine antibodies have also been reported in humans (46, 48) . An antiidiotypic response, if capable of blocking the antibody-combining site, would prevent antibody-targeted particles from binding their target cells even if their circulation were prolonged. The same situation would apply to an antibody response directed against those determinants of carbohydrates or hormones used for targeting that were essential for target binding. In these circumstances, if the targeted particles carried drugs potentially toxic for the RES, then reduction of the rate of clearance of these particles might reduce their toxicity for phagocytic cells.
